Skip to main
ENOV

Enovis Corp (ENOV) Stock Forecast & Price Target

Enovis Corp (ENOV) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enovis is expected to see steady growth and increasing operational leverage in the future, strengthened by its multi-segmented approach and new product launches. Its exposure to the bone growth stimulation market may be limited, resulting in minimal impact from potential reimbursement reductions. While there are risks such as tariff exposure and competition, overall, Enovis has a strong financial position and potential for future growth.

Bears say

Enovis is currently facing several challenges that may hinder its growth in the near term, including potential pricing pressure and market share erosion as new competitors enter the market with the company's reclassified products. Additionally, the company's strong reliance on its older Prevention & Recovery segment may limit its growth potential and result in slower-than-expected top-line growth. These challenges, combined with the potential for continued tariff pressures and unsuccessful M&A integration, contribute to our negative outlook on Enovis's stock.

Enovis Corp (ENOV) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enovis Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enovis Corp (ENOV) Forecast

Analysts have given Enovis Corp (ENOV) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Enovis Corp (ENOV) has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enovis Corp (ENOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.